Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

Comparative Price Performance Over Time

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
BGNE BeiGene		$194.32	$126.97 ▼ $248.16	$18.03B	0.57	283,704 shs	331,608 shs
BNTX BioNTech	$90.29 -0.8%	$110.45	$76.53 ▼ $131.49	$21.67B	0.3	832,894 shs	1.14 million shs
GSK GSK	$37.82 -2.4%	$37.41	$31.72 ▼ $45.93	$78.28B	0.58	4.47 million shs	5.29 million shs
TAK Takeda Pharmaceutical	$14.91 +0.2%	$14.23	$12.58 ▼ $15.31	$47.43B	0.46	1.80 million shs	1.37 million shs

Unlock the Potential in Options Trading

Options trading isn’t just for the Wall Street elite; it’s an accessible strategy for anyone armed with the proper knowledge. Think of options as a strategic toolkit, with each tool designed for a specific financial task. Get this report to learn how options trading can help you use the market’s volatility to your advantage.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
BGNE BeiGene	0.00%	0.00%	0.00%	0.00%	+16.00%
BNTX BioNTech	-0.85%	-6.97%	-20.04%	-20.76%	-3.04%
GSK GSK	-2.55%	-2.14%	+0.62%	+11.83%	-10.83%
TAK Takeda Pharmaceutical	+0.20%	-0.96%	+3.51%	+12.58%	+9.03%

Remove Ads

Compare MarketRank™

Company	Overall Score	Analyst's Opinion	Short Interest Score	Dividend Strength	News and Social Media Sentiment	Company Ownership	Earnings & Valuation
BGNE BeiGene	1.2318 of 5 stars	3.4	0.0	0.0	0.0	0.8	0.6
BNTX BioNTech	2.8314 of 5 stars	4.4	2.0	0.0	2.4	0.8	0.6
GSK GSK	2.8278 of 5 stars	2.3	5.0	2.5	2.9	0.0	1.3
TAK Takeda Pharmaceutical	2.2305 of 5 stars	0.0	3.0	2.5	1.9	0.0	2.5

Compare Analyst Forecasts

Company	Consensus Rating Score	Consensus Rating	Consensus Price Target	% Upside from Current Price
BGNE BeiGene	2.83	Moderate Buy	$253.92	∞ Upside
BNTX BioNTech	2.89	Moderate Buy	$143.44	58.86% Upside
GSK GSK	2.60	Moderate Buy	$43.25	14.35% Upside
TAK Takeda Pharmaceutical	0.00	N/A	N/A	N/A

Current Analyst Ratings Breakdown

Latest BNTX, GSK, TAK, and BGNE Analyst Ratings

Date	Company	Brokerage	Action	Rating	Price Target
4/1/2025	BNTX BioNTech	HC Wainwright Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Buy ➝ Buy	$150.00 ➝ $145.00
3/13/2025	BNTX BioNTech	Citigroup Subscribe to MarketBeat All Access for the recommendation accuracy rating	Initiated Coverage	Buy	$145.00
3/11/2025	BNTX BioNTech	Morgan Stanley Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Overweight ➝ Overweight	$145.00 ➝ $139.00
3/11/2025	BNTX BioNTech	Canaccord Genuity Group Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$171.44 ➝ $171.44
3/11/2025	BNTX BioNTech	BMO Capital Markets Subscribe to MarketBeat All Access for the recommendation accuracy rating	Boost Price Target	Outperform ➝ Outperform	$130.00 ➝ $143.00
2/12/2025	GSK GSK	Morgan Stanley Subscribe to MarketBeat All Access for the recommendation accuracy rating	Initiated Coverage	Equal Weight
1/10/2025	BNTX BioNTech	Truist Financial Subscribe to MarketBeat All Access for the recommendation accuracy rating	Initiated Coverage	Buy	$172.00

(Data available from 4/2/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Compare Sales & Book Value

Company	Annual Revenue	Price/Sales	Cashflow	Price/Cash	Book Value	Price/Book
BGNE BeiGene	$3.32B	0.00	N/A	N/A	$37.10 per share	0.00
BNTX BioNTech	$2.75B	7.88	$3.88 per share	23.25	$92.17 per share	0.98
GSK GSK	$31.38B	2.49	$5.98 per share	6.32	$8.07 per share	4.69
TAK Takeda Pharmaceutical	$4.58T	0.01	$3.49 per share	4.27	$15.39 per share	0.97

Compare Profitability & Earnings

Company	Net Income	EPS	Trailing P/E Ratio	Forward P/E Ratio	P/E Growth	Net Margins	Return on Equity (ROE)	Return on Assets (ROA)	Next Earnings Date
BGNE BeiGene	-$881.71M	-$8.24	N/A	N/A	N/A	-25.94%	-25.12%	-14.95%	N/A
BNTX BioNTech	$1.01B	-$3.00	N/A	N/A	N/A	-15.16%	-2.35%	-2.05%	5/5/2025 (Estimated)
GSK GSK	$3.29B	$1.59	23.79	8.13	1.12	8.13%	48.59%	11.11%	4/30/2025 (Estimated)
TAK Takeda Pharmaceutical	$994.06M	$0.40	37.26	9.03	0.24	4.53%	9.39%	4.53%	5/8/2025 (Estimated)

Latest BNTX, GSK, TAK, and BGNE Earnings

Date	Quarter	Company	Consensus Estimate	Reported EPS	Beat/Miss	Gap EPS	Revenue Estimate	Actual Revenue
4/30/2025	N/A	GSK GSK	$1.06	N/A	N/A	N/A	$7.52 billion	N/A
3/10/2025	Q4 24	BNTX BioNTech	$0.38	$1.08	+$0.70	$1.15	$1.24 billion	$1.19 billion
2/5/2025	Q4 2024	GSK GSK	$0.44	$0.59	+$0.15	$0.26	$7.75 billion	N/A
1/30/2025	Q3 2025	TAK Takeda Pharmaceutical	$0.34	$0.42	+$0.08	$0.05	N/A	N/A

Compare Dividends

Company	Annual Payout	Dividend Yield	3-Year Dividend Growth	Payout Ratio	Years of Consecutive Growth
BGNE BeiGene	N/A	N/A	N/A	N/A	N/A
BNTX BioNTech	$1.53	1.69%	N/A	N/A	N/A
GSK GSK	$1.57	4.15%	-17.33%	98.74%	N/A
TAK Takeda Pharmaceutical	$0.53	3.56%	-8.36%	132.50%	N/A

Latest BNTX, GSK, TAK, and BGNE Dividends

Announcement	Company	Period	Amount	Yield	Ex-Dividend Date	Record Date	Payable Date
2/5/2025	GSK GSK	quarterly	$0.3932	4.2%	2/21/2025	2/21/2025	4/10/2025

(Data available from 1/1/2013 forward)

Compare Debt

Company	Debt-to-Equity Ratio	Current Ratio	Quick Ratio
BGNE BeiGene	0.05	1.93	1.72
BNTX BioNTech	0.01	7.33	7.21
GSK GSK	1.12	0.78	0.52
TAK Takeda Pharmaceutical	0.63	1.31	0.72

Compare Ownership

Institutional Ownership

Company	Institutional Ownership
BGNE BeiGene	48.55%
BNTX BioNTech	15.52%
GSK GSK	15.74%
TAK Takeda Pharmaceutical	9.17%

Insider Ownership

Company	Insider Ownership
BGNE BeiGene	7.43%
BNTX BioNTech	19.20%
GSK GSK	10.00%
TAK Takeda Pharmaceutical	0.04%

Compare Miscellaneous Stats

Company	Employees	Shares Outstanding	Free Float	Optionable
BGNE BeiGene	9,000	97.62 million	90.20 million	Optionable
BNTX BioNTech	3,080	239.97 million	193.71 million	Optionable
GSK GSK	90,100	2.07 billion	1.87 billion	Optionable
TAK Takeda Pharmaceutical	47,300	3.18 billion	3.18 billion	Optionable

BNTX, GSK, TAK, and BGNE Headlines

Recent News About These Companies

Head-To-Head Review: Xenetic Biosciences (NASDAQ:XBIO) versus Takeda Pharmaceutical (NYSE:TAK)

April 2 at 1:36 AM | americanbankingnews.com

Takeda dedicated to advanced healthcare

April 1 at 3:04 AM | vir.com.vn

TAK vs. DSNKY: Which Stock Should Value Investors Buy Now?

March 31 at 12:45 PM | zacks.com

Harmony Biosciences Names Adam Zaeske as Chief Commercial Officer

March 30 at 11:29 PM | msn.com

Takeda reaffirms patient-centric mission in Vietnam: GM

March 30 at 8:27 AM | tuoitrenews.vn

Why Wave Life Sciences Ltd.’s (WVE) Stock Is Down 10.08%

March 28, 2025 | aaii.com

Takeda Canada says Health Canada expands marketing authorization for HyQvia

March 28, 2025 | markets.businessinsider.com

Charles Schwab Investment Management Inc. Raises Stock Holdings in Takeda Pharmaceutical Company Limited (NYSE:TAK)

March 28, 2025 | marketbeat.com

Takeda's HyQvia® receives expanded market authorization as maintenance therapy for chronic inflammatory demyelinating polyneuropathy (CIDP)

March 27, 2025 | newswire.ca

Takeda Pharmaceutical (NYSE:TAK) Sets New 12-Month High - Time to Buy?

March 25, 2025 | marketbeat.com

Cell and gene therapy market set to grow at 44% CAGR through 2030, reveals GlobalData

March 25, 2025 | financialexpress.com

Global pharma giants double down on China, betting on long-term growth

March 24, 2025 | globaltimes.cn

Summit Global Investments Has $9.66 Million Stake in Takeda Pharmaceutical Company Limited (NYSE:TAK)

March 23, 2025 | marketbeat.com

69,083 Shares in Takeda Pharmaceutical Company Limited (NYSE:TAK) Bought by Boston Partners

March 23, 2025 | marketbeat.com

Natixis Advisors LLC Acquires 21,539 Shares of Takeda Pharmaceutical Company Limited (NYSE:TAK)

March 23, 2025 | marketbeat.com

BioLife invests $4M to recycle biohazardous plastic waste

March 21, 2025 | plasticsnews.com

Signaturefd LLC Raises Stake in Takeda Pharmaceutical Company Limited (NYSE:TAK)

March 21, 2025 | marketbeat.com

Is Takeda Pharmaceutical Co. (TAK) a Great Value Stock Right Now?

March 19, 2025 | zacks.com

Takeda Pharmaceutical (NYSE:TAK) Hits New 12-Month High - What's Next?

March 18, 2025 | marketbeat.com

Protagonist Therapeutics Named to Fast Company’s Annual List of the World’s Most Innovative Companies of 2025

March 18, 2025 | miamiherald.com

Takeda Pharmaceutical Company Limited (NYSE:TAK) Position Lowered by Brandes Investment Partners LP

March 16, 2025 | marketbeat.com

New MarketBeat Followers Over Time

Media Sentiment Over Time

Top Headlines

View All

Joby Aviation: From Prototype to Profitability
By Jeffrey Neal Johnson | March 11, 2025
View Joby Aviation: From Prototype to Profitability
Tesla Stock: Finding a Bottom May Take Time
By Chris Markoch | March 4, 2025
View Tesla Stock: Finding a Bottom May Take Time
5 Hot Stock Buys for Investors in April
By Thomas Hughes | April 1, 2025
View 5 Hot Stock Buys for Investors in April
Advanced Micro Devices Eyes AI Market Growth—Is AMD a Buy?
By Thomas Hughes | March 18, 2025
View Advanced Micro Devices Eyes AI Market Growth—Is AMD a Buy?
Tariffs Won’t Stop These 3 Stocks From Rising
By Chris Markoch | March 5, 2025
View Tariffs Won’t Stop These 3 Stocks From Rising

BNTX, GSK, TAK, and BGNE Company Descriptions

BeiGene NASDAQ:BGNE

BeiGene, Ltd., through its subsidiaries, engages in the development and commercialization of oncology medicines worldwide. Its products include BRUKINSA to treat various blood cancers; TEVIMBRA to treat various solid tumor and blood cancers; PARTRUVIX for the treatment of various solid tumor malignancies; XGEVA to treat bone metastases from solid tumors and multiple myeloma, as well as giant cell tumor of bone; BLINCYTO to treat acute lymphoblastic leukemia; KYPROLIS to treat R/R multiple myeloma; REVLIMID to treat multiple myeloma; VIDAZA to treat myelodysplastic syndromes, chronic myelomonocyte leukemia, and acute myeloid leukemia; SYLVANT to treat idiopathic multicentric castleman disease; QARZIBA to treat neuroblastoma; POBEVCY to treat metastatic colorectal cancer, liver cancer, and non-small cell lung cancer (NSCLC); BAITUOWEI, to treat breast and prostate cancers; TAFINLAR and MEKINIST to treat NSCLC and melanoma; VOTRIENT for advance renal cell carcinoma; AFINITOR for advance renal cell carcinoma, NET, SEGA, & breast cancers; and ZYKADIA to treat ALK + NSCLC. The company is also developing inhibitors comprising Sonrotoclax (BGB-11417), BGB-10188, BGB-21447, Ociperlimab (BGB-A1217), Surzebiclimab (BGB-A425), BGB-15025, BGB-26808, Lifirafenib (BGB-283), BGB-3245, BGB-30813, and BGB-43395; antibodies, including Zanidatamab, BGB-A445, and BGB-A3055, as well as BGB-16673, a BTK-targeted CDAC, and BGB-24714, a SMAC mimetic. It has collaborations with Shoreline Biosciences, Inc., Amgen Inc., Novartis AG, Bristol Myers Squibb company, Shandong Luye Pharmaceutical Co., Ltd., Nanjing Leads Biolabs, Inc., EUSA Pharma, Assembly Biosciences, Inc., Bio-Thera Solutions, Ltd., and Nanjing Leads Biolabs Co., Ltd. The company was incorporated in 2010 and is based in Grand Cayman, the Cayman Islands.

BioNTech NASDAQ:BNTX

$90.29 -0.77 (-0.85%)

Closing price 04/1/2025 04:00 PM Eastern

Extended Trading

$89.94 -0.35 (-0.39%)

As of 04/1/2025 07:56 PM Eastern

BioNTech SE, a biotechnology company, develops and commercializes immunotherapies for cancer and other infectious diseases. The company is developing FixVac product candidates, including BNT111, which is in Phase II clinical trial for advance melanoma; BNT112 that is in Phase I/IIa clinical trial for prostate cancer; BNT113, which is in Phase II clinical trial to treat HPV 16+ head and neck cancers; BNT114 to treat triple negative breast cancer; BNT115, which is in Phase I clinical trial in ovarian cancer; and BNT116, which is in Phase I clinical trial for non-small cell lung cancer. It develops BNT122, which is in Phase II clinical trial for first-line melanoma and in Phase I clinical trial to treat multiple solid tumors; BNT131 that is in Phase I clinical trial for multiple solid tumors; BNT141 and BNT142 that are in Phase I clinical trial to treat multiple solid tumors; BNT151, BNT152, and BNT153 to treat solid tumors; BNT211 to treat multiple solid tumors, and BNT221 for pancreatic and other cancers; BNT311 which are in Phase II clinical trial to treat metastatic non-small cell lung cancer and Phase I/II clinical trial to treat multiple solid tumors; and BNT312, which is in Phase 2 clinical trial to treat multiple solid tumors, as well as ONC-392, which is in Phase III clinical trial to treat ovarian cancer and Phase I/II clinical trial to treat multiple solid tumors. It develops BNT321, an IgG1 monoclonal antibody in Phase I clinical trial for pancreatic cancer; BNT411, a small molecule immunomodulator product candidate in Phase I clinical trial for solid tumors; BNT322, which is in Phase I/Ib clinical trial for multiple solid tumors; and prophylactic vaccine for shingles, malaria, tuberculosis, HSV-2, and other infectious diseases. It has collaborations with Genentech, Inc.; Sanofi S.A.; Genmab A/S; Pfizer Inc.; Shanghai Fosun Pharmaceutical (Group) Co., Ltd; and Ryvu Therapeutics S.A. BioNTech SE was incorporated in 2008 and is based in Mainz, Germany.

GSK NYSE:GSK

$37.82 -0.92 (-2.37%)

Closing price 04/1/2025 03:59 PM Eastern

Extended Trading

$37.98 +0.16 (+0.42%)

As of 04/1/2025 07:58 PM Eastern

GSK plc, together with its subsidiaries, engages in the research, development, and manufacture of vaccines, and specialty and general medicines to prevent and treat disease in the United Kingdom, the United States, and internationally. It operates through two segments, Commercial Operations and Total R&D. The company offers shingles, meningitis, respiratory syncytial virus, flu, polio, influenza, and pandemic vaccines. It also provides medicines for HIV, oncology, respiratory/immunology, and other specialty medicine products, as well as inhaled medicines for asthma and chronic obstructive pulmonary disease, and antibiotics for infections. It has a collaboration agreement with CureVac to develop mRNA-based influenza vaccines, and with Wave Life Sciences and Elsie Biotechnologies, Inc for oligonucleotide platform development. The company was formerly known as GlaxoSmithKline plc and changed its name to GSK plc in May 2022. GSK plc was founded in 1715 and is headquartered in Brentford, the United Kingdom.

Takeda Pharmaceutical NYSE:TAK

$14.90 +0.04 (+0.24%)

Closing price 04/1/2025 03:58 PM Eastern

Extended Trading

$14.94 +0.03 (+0.20%)

As of 04/1/2025 07:21 PM Eastern

Takeda Pharmaceutical Company Limited engages in the research, development, manufacture, marketing, and out-licensing of pharmaceutical products in Japan and internationally. It offers pharmaceutical products in the areas of gastroenterology, rare diseases, plasma derived therapies, immunology, oncology, and neuroscience. The company provides its products under the Entyvio, Gattex/Revestive, Takecab/Vocinti, Alofisel, Dexilant, Pantoloc/Controloc, Adynovate/Adynovi, Feiba, Recombinate, Hemofil/Immunate/Immunine, Takhzyro, Livtencity, Elaprase, Replagal, Advate, Flexbumin, Vpriv, Gammagard Liquid/Kiovig, Hyqvia, Cuvitru, Exkivity, Ninlaro, Velcade, Azilva-F, Lotriga, Iclusig, Leuplin/Enantone, Adcetris, vyvanse/elvanse, Trintellix, and Alunbrig brands. It has in-license agreement with BioMarin, Luxna Biotech, GlaxoSmithKline, Halozyme, and Kamada; collaboration with Neurocrine Biosciences, Inc., Seagen Inc., Anima Biotech, Denali Therapeutics, KSQ Therapeutics, Noile-Immune Biotech, Center for iPS Cell Research Application, Kyoto University (CiRA), and Charles River Laboratories; licensing agreement with Mirum Pharmaceuticals and Twist Bioscience, UCSD/Fortis Advisors, PeptiDream, MD Anderson Cancer Center, Teva Pharmaceutical Industries, and Xenetic Biosciences; collaboration and licensing agreement with Arrowhead Pharmaceuticals Inc., Engitix, Genevant Sciences Corporation, Sosei Heptares, Zedira/Dr. Falk Pharma, Exelixis, Inc., GlaxoSmithKline, Heidelberg Pharma, HUTCHMED, Presage Biosciences, Codexis, Inc., Ensoma, Envozyne, KM Biologics, and Selecta BioScience, and Ovid Therapeutics Inc.; and collaboration with ZEDIRA GmbH and Dr. Falk Pharma GmbH. It has research collaboration and licensing agreement with Crescendo Biologics, Code Bio, Immusoft, Poseida Therapeutics, and Selecta Biosciences. The company was founded in 1781 and is headquartered in Tokyo, Japan.

More Stock Comparisions from MarketBeat

More Stock Ideas from MarketBeat

Stock Lists

Low Priced Stocks

Stocks By Exchange

Latest Stock Ideas

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Compare Stocks

Comparative Price Performance Over Time